Skip to content

Influence of new guidelines for the therapy of antiphospholipid syndrome

Influence of new guidelines for the therapy of antiphospholipid syndrome - APS_IIT

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00035485
Enrollment
400
Registered
2025-04-28
Start date
2025-08-15
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D68.6

Interventions

Group 1: Patients with confirmed antiphospholipid syndrome: classification and course of therapy, followup regarding reccurrences, thrombotic events, pregnancies by structured phone interview

Sponsors

Universitätsklinikum Frankfurt, Hämophiliezentrum
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: - confirmed diagnosis of antiphospholipid syndrome - for followup: signed consent

Exclusion criteria

Exclusion criteria: - no confirmed diagnosis of antiphospholipid syndrome - for followup: no signed consent

Design outcomes

Primary

MeasureTime frame
• APS-classification according to Sapporo/Sydney-criteria 2006 at the time of initial diagnosis • APS-classification according to 2023 ACR/EULAR and risk stratification at the time of initial diagnosis • adjusted Global Antiphospholipid Syndrome Score at the time of initial diagnosis Data will be collected from patient records.

Secondary

MeasureTime frame
• gender • age at initial APS diagnosis, rezidive • underlying disease • anamnesis, family anamnesis • further thrombophilic risk factors • Laboratory parameters at initial episode and reccurence including PTT, thrombocytes, Lupus-sensitive aPTT, Diluted Russel Viper Venom Time (DRVVT screen/ratio), anti-ß2-glycoprotein /anti- cardiolipin antibodies • symptoms • therapy • outcome • long term data about recurrence, morbidity, pregnancies

Countries

Germany

Contacts

Public ContactWolfgang Miesbach

Universitätsklinikum Frankfurt, Hämophiliezentrum

Wolfgang.miesbach@unimedizin-ffm.de+49 69 6301 5051

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026